Intech Biopharm

Focus: Intech Biopharm is a Taiwan-based biotechnology company focused on inhaled small molecule and combination drugs for respiratory indications. Founded in 2010, the company specializes in asthma treatments with a clinical-stage pipeline.

Respiratory

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Intech Biopharm

AI assessmentNot Hiring

No open roles listed right now. Follow Intech Biopharm to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

11 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Albuterol Sulfate inhalation aerosol 108 mcg per actuation

Mild Asthma

N/A

Clinical Trials (1)

NCT04912596Pharmacodynamic Equivalence of the Test and Reference Metered Dose Inhalers (MDIs) Containing Albuterol Sulfate in Adult Patients With Stable Mild Asthma

N/A

Help build intelligence for Intech Biopharm

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Focused therapeutic area (respiratory) offers deep specialization opportunity in inhaled drug delivery and formulation
Early-stage company (founded 2010) provides potential for meaningful impact on drug development from Phase 1 through commercialization
Combination therapy focus (e.g., Budesonide/Procaterol) positions work on clinically relevant multi-mechanism approaches

Watch Out For

Pre-revenue status with no commercial products means no revenue runway or established market position to fund operations
Pipeline heavily concentrated in early phases (6 Phase 1 programs, 1 Phase 2, 0 Phase 3) indicates multi-year development timeline with clinical risk
Currently zero open positions and no hiring activity suggests limited near-term growth or expansion plans
Minimal public visibility (0 publications) and undisclosed financials raise transparency and stability concerns

Generated by Claude from Intech Biopharm's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Albuterol Sulfate inhalation aerosol 108mcg per actuation

Healthy

N/A

Clinical Trials (1)

NCT04803734Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108 mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90 mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

N/A

Albuterol Sulfate Inhalation Aerosol 108mcg per actuation

Healthy

N/A

Clinical Trials (1)

NCT05300087Bioequivalence Between Albuterol Sulfate Inhalation Aerosol 108mcg Per Actuation and Proair HFA (Albuterol Sulfate) Inhalation Aerosol 90mcg Per Actuation in Healthy Volunteers Under Fasting Conditions

N/A

Fluticasone propionate

Asthma

Phase 1

Clinical Trials (1)

NCT02466503Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Phase 1

Budesonide

Asthma

Phase 1

Clinical Trials (1)

NCT04494321A Bioequivalence Pivotal Study of SYN010 HFA Inhaler and Symbicort® 160/4.5 in Healthy Volunteers Without Charcoal Block